Advice

following a resubmission considered under the end of life / orphan medicine process:

paclitaxel albumin (Abraxane®) is accepted for use within NHS Scotland.

Indication under review: in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

In a randomised, phase III, open-label study paclitaxel albumin plus gemcitabine treatment improved median overall survival by 1.8 months compared with gemcitabine alone.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Download detailed advice181KB (PDF)

Download

Medicine details

Medicine name:
paclitaxel albumin (Abraxane)
SMC ID:
968/14
Indication:
In combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
Pharmaceutical company
Celgene Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Resubmission
Status
Accepted
Date advice published:
09 February 2015